Overview

Ketamine for Major Depressive Disorder

Status:
Unknown status

Trial end date:
2019-06-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to measure the amount of ketamine in blood over time in subjects diagnosed with Major Depressive Disorder (MDD) and explore the anti-depressive effects of ketamine delivered by transdermal patch.

Phase:

Phase 1

Details

Lead Sponsor:

Shenox Pharmaceuticals, LLC

Treatments:

Ketamine